

Andrew S Poklepovic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4318260/publications.pdf>

Version: 2024-02-01

47
papers

1,596
citations

279701

23
h-index

315616

38
g-index

50
all docs

50
docs citations

50
times ranked

2067
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2022, 399, 1718-1729.	6.3	236
2	HDAC inhibitors enhance the immunotherapy response of melanoma cells. <i>Oncotarget</i> , 2017, 8, 83155-83170.	0.8	108
3	Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2647-2655.	0.8	94
4	Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer. <i>Autophagy</i> , 2014, 10, 1478-1480.	4.3	77
5	Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. <i>Oncogene</i> , 2019, 38, 5890-5904.	2.6	63
6	HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 90262-90277.	0.8	57
7	Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	56
8	The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 16367-16386.	0.8	55
9	PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. <i>Cancer Biology and Therapy</i> , 2014, 15, 758-767.	1.5	48
10	Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic. <i>Frontiers in Oncology</i> , 2016, 6, 142.	1.3	45
11	Nexavar/Stivarga and Viagra Interact to Kill Tumor Cells. <i>Journal of Cellular Physiology</i> , 2015, 230, 2281-2298.	2.0	44
12	The afatinib resistance of <i>in vivo</i> generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. <i>Oncotarget</i> , 2016, 7, 19620-19630.	0.8	43
13	Pazopanib and HDAC inhibitors interact to kill sarcoma cells. <i>Cancer Biology and Therapy</i> , 2014, 15, 578-585.	1.5	42
14	Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress-Inducing Drugs. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2384-2398.	1.9	42
15	[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells. <i>Cancer Biology and Therapy</i> , 2017, 18, 705-714.	1.5	41
16	PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. <i>Oncotarget</i> , 2017, 8, 1449-1468.	0.8	41
17	AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication. <i>Biochemical Pharmacology</i> , 2020, 182, 114227.	2.0	39
18	Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, G1± _q and G1± ₁₁ and kill uveal melanoma cells. <i>Cancer Biology and Therapy</i> , 2019, 20, 700-710.	1.5	37

#	ARTICLE	IF	CITATIONS
19	HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells. <i>Cancer Biology and Therapy</i> , 2014, 15, 305-316.	1.5	32
20	The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. <i>Cancer Biology and Therapy</i> , 2018, 19, 132-137.	1.5	32
21	BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 386.	1.8	32
22	Considering adjuvant therapy for stage II melanoma. <i>Cancer</i> , 2020, 126, 1166-1174.	2.0	32
23	[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NF κ B compensatory survival signaling. <i>Oncotarget</i> , 2016, 7, 23608-23632.	0.8	27
24	The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells. <i>Cancer Biology and Therapy</i> , 2018, 19, 525-533.	1.5	26
25	A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. <i>Cancer</i> , 2020, 126, 3464-3470.	2.0	24
26	The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells. <i>Cancer Biology and Therapy</i> , 2018, 19, 786-796.	1.5	23
27	[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration. <i>Oncotarget</i> , 2018, 9, 6062-6074.	0.8	23
28	Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 40398-40417.	0.8	23
29	Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance. <i>Cancer Biology and Therapy</i> , 2015, 16, 1660-1670.	1.5	20
30	Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS. <i>Oncotarget</i> , 2016, 7, 17290-17300.	0.8	18
31	The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells. <i>Cellular Signalling</i> , 2020, 70, 109573.	1.7	15
32	Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib. <i>Biochemical Pharmacology</i> , 2021, 190, 114642.	2.0	12
33	Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. <i>Investigational New Drugs</i> , 2013, 31, 937-942.	1.2	11
34	Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers. <i>Cardio-Oncology</i> , 2018, 4, .	0.8	10
35	The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib. <i>Frontiers in Oncology</i> , 2019, 9, 650.	1.3	10
36	Prognostic Value of Low Tumor Burden in Patients With Melanoma. <i>Oncology</i> , 2018, 32, e90-e96.	0.4	10

#	ARTICLE	IF	CITATIONS
37	Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43. <i>Aging</i> , 2021, 13, 17097-17117.	1.4	9
38	The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells. <i>Cancer Biology and Therapy</i> , 2018, 19, 239-247.	1.5	7
39	Fingolimod Augments Monomethylfumarate Killing of GBM Cells. <i>Frontiers in Oncology</i> , 2020, 10, 22.	1.3	7
40	Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate]. <i>Cellular Signalling</i> , 2020, 68, 109525.	1.7	6
41	Immunotherapy for Metastatic Melanoma with Right Atrial Involvement in a Patient with Rheumatoid Arthritis. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-4.	0.2	5
42	Metabolism of Histone Deacetylase Proteins Oponizes Tumor Cells to Checkpoint Inhibitory Immunotherapies. <i>Immunometabolism</i> , 2020, 2, .	0.7	5
43	Neratinib kills Bâ€RAF V600E melanoma via ROSâ€dependent autophagosome formation and death receptor signaling. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 66-77.	1.5	3
44	The development of multi-kinase inhibitors as pancreatic cancer therapeutics. <i>Anti-Cancer Drugs</i> , 2021, 32, 779-785.	0.7	2
45	Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells. <i>Frontiers in Oncology</i> , 2021, 11, 723966.	1.3	2
46	Kinase inhibitors: look beyond the label on the bottle. , 2019, 2, 1032-1043.		0
47	The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant. <i>Case Reports in Obstetrics and Gynecology</i> , 2022, 2022, 1-5.	0.2	0